About: Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models
Creator	Orlandi, Chiara Pyzik, Michal Brigham And Women's Hospital, Jones Hessell, Ann Lewis, George Reeves, R Schmaljohn, Alan
Source	PMC
abstract	Longstanding discordances and enigmas persist as to the specificities and other properties of antibodies (Abs) most effective in preventing or limiting many viral infections in mammals; in turn, failure to decipher key complexities has added to headwinds for both Ab-based therapeutic approaches and rational vaccine design. More recently, experimental approaches have emerged—and continue to emerge—for discerning the functional role of Ab structure, especially the Fc portion of antibody, in combating viral infections in vivo. A wide range of in vitro measures of antibody activity, from neutralization to antibody-dependent cell mediated cytotoxicity (ADCC)—each of these terms representing only an operational notion defined by the particulars of a given assay—are poised for assignment of both relevance and reliability in forecasting outcomes of infection. Of the several emergent technical opportunities for clarity, attention here is drawn to three realms: the increasing array of known modifications that can be engineered into Abs to affect their in vivo activities; the improvement of murine models involving knockouts and knock-ins of host genes including Fc receptors; and the development of additional virological design tools to differentiate Abs that act primarily by inhibiting viral entry from antibodies that mainly target viral antigens (Ags) on cell surfaces. To illustrate some of the opportunities with either zoonotic (emerging, spillover) or ancient human-adapted viruses, we draw examples from a wide range of viruses that affect humans.
has issue date	2019-07-17(xsd:dateTime)
bibo:doi	10.3389/fimmu.2019.01602
bibo:pmid	31379822
has license	cc-by
sha1sum (hex)	3a676f4ebe85b17d5aedd055c0af967760e13e64
schema:url	https://doi.org/10.3389/fimmu.2019.01602
resource representing a document's title	Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models
has PubMed Central identifier	PMC6652135
has PubMed identifier	31379822
schema:publication	Front Immunol
resource representing a document's body	covid:3a676f4ebe85b17d5aedd055c0af967760e13e64#body_text
is schema:about of	named entity 'tools' named entity 'viral antigens' named entity 'antibody' named entity 'complexities' named entity 'experimental' named entity 'key' named entity 'differentiate' named entity 'wide range' named entity 'vaccine' named entity 'operational' named entity 'host' named entity 'vivo' named entity 'NEUTRALIZATION' named entity 'CONTINUE' named entity 'TOOLS' named entity 'HERE' named entity 'ZOONOTIC' named entity 'DRAW' named entity 'CLARITY' named entity 'INVOLVING' named entity 'APPROACHES' named entity 'TECHNICAL' named entity 'DEVELOPMENT' named entity 'INHIBITING' named entity 'SURFACES' named entity 'ANTIBODIES' named entity 'PREVENTING' named entity 'THESE' named entity 'ADDITIONAL' named entity 'VIRAL INFECTIONS' named entity 'ACTIVITY' named entity 'VIROLOGICAL' named entity 'ASSAY' named entity 'PROPERTIES' named entity 'MURINE' named entity 'SPECIFICITIES' named entity 'ACT' named entity 'EMERGE' named entity 'IN VITRO' named entity 'INS' named entity 'NOTION' named entity 'IN VIVO' named entity 'KEY' named entity 'HAVE' named entity 'STRUCTURE' named entity 'PORTION' named entity 'TARGET' named entity 'RELEVANCE' named entity 'FC RECEPTORS' named entity 'ADDED' named entity 'FUNCTIONAL ROLE' named entity 'EFFECTIVE' named entity 'POISED' named entity 'GIVEN' named entity 'BASED' named entity 'IMPROVEMENT' named entity 'LIMITING' named entity 'HUMAN' named entity 'GENES' named entity 'WIDE' named entity 'MAMMALS' named entity 'INFECTION' named entity 'INCLUDING' named entity 'MODELS' named entity 'ATTENTION' named entity 'MEASURES' named entity 'RANGE' named entity 'ANIMAL MODELS' named entity 'KNOWN' named entity 'AFFECT' named entity 'ANTIVIRAL ANTIBODY' named entity 'FUNCTIONS' named entity 'ANTIBODY' named entity 'THERAPEUTIC' named entity 'DIFFERENTIATE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software